| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/06/2013 | CN102958539A Full-length immunoglobulins of the IgG isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament |
| 03/06/2013 | CN102958538A Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| 03/06/2013 | CN102958537A Tnf-alpha binding proteins |
| 03/06/2013 | CN102958536A Treatment of vascularized pigment epithelial detachment with anti-vegf therapy |
| 03/06/2013 | CN102958535A Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| 03/06/2013 | CN102958534A Notch1 binding agents and methods of use thereof |
| 03/06/2013 | CN102952849A Application of protein coded by gene LIMG and antibody thereof in breast cancer diagnosis and/or treatment |
| 03/06/2013 | CN102952799A Applications of gene and protein coded thereby to promotion of cell cytoplasm cleavage and cell proliferation as well as research and development of drugs |
| 03/06/2013 | CN102952785A Porcine pseudorabies virus, and vaccine composition and applications thereof |
| 03/06/2013 | CN102952784A Method for producing RHD (rabbit haemorrhagic disease) vaccine by use of cell line and product thereof |
| 03/06/2013 | CN102952192A Fusion protein containing Exendin-4 and application thereof |
| 03/06/2013 | CN102952191A Fully human CD33 single-chain antibody ZJL101 and applications thereof |
| 03/06/2013 | CN102952190A Microbubble membrane protein and application thereof |
| 03/06/2013 | CN102949733A Compound type therapeutic hepatitis B gene vaccine and construction method thereof |
| 03/06/2013 | CN102949720A Biosecurity multifactor blood serum production method for African swine fever |
| 03/06/2013 | CN102949719A Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1 |
| 03/06/2013 | CN102949718A Triple live vaccine for swine transmissible gastroenteritis virus, swine epidemic diarrhea virus and swine rotavirus |
| 03/06/2013 | CN102949717A Novel hepatitis B vaccine preparation containing poly I:C adjuvant |
| 03/06/2013 | CN102949716A Method for preparing inactivated rabies vaccine for animal by bioreactor |
| 03/06/2013 | CN102949715A Method for preparing inactivated Japanese encephalitis vaccine by bioreactor |
| 03/06/2013 | CN102949714A Swine Streptococcosis trivalent inactivated vaccine and preparation method thereof |
| 03/06/2013 | CN102949713A Novel bacillus subtilis multi-valent vector-based vaccine and application thereof |
| 03/06/2013 | CN102949708A Application of human sDR5 (soluble death receptor 5) protein or sDR5-Fc (fragment crystallizable) antibody fusion protein as pharmaceutical drugs for myocardial infarction |
| 03/06/2013 | CN102399754B H9N2 avian influenza virus vaccine strain and application of H9N2 avian influenza virus vaccine strain in immune protection |
| 03/06/2013 | CN102238959B Composition comprising bacillus calmette guerin polysaccharides and bacillus calmette guerin nucleic acids and use of preparing medicament thereof |
| 03/06/2013 | CN102115492B Vascular endothelial growth factor receptor partial polypeptide and application thereof |
| 03/06/2013 | CN101934074B Porcine circovirus II vaccine and production method thereof |
| 03/06/2013 | CN101217977B Thermoreversible immuno-adjuvant emulsion |
| 03/05/2013 | US8389694 Biologically active antibodies recognizing a cell surface molecule selectively expressed on living mouse natural type one (I) interferon producing cells |
| 03/05/2013 | US8389690 Antibodies to JTT-1 protein and cells secreting such antibodies |
| 03/05/2013 | US8389689 Anti-GLP-1R antibodies and their uses |
| 03/05/2013 | US8389682 Inhibiting Staphylococcus epidermidis infections |
| 03/05/2013 | US8389679 Targeted antimicrobial moieties |
| 03/05/2013 | US8389678 Protein fragments of virB10 and sero-detection of Anaplasma phagocytophilum |
| 03/05/2013 | US8389495 Olioodeoxynucleotide and its use to induce an immune response |
| 03/05/2013 | US8389474 Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
| 03/05/2013 | US8389472 Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| 03/05/2013 | US8389275 Fusion proteins of HIV regulatory/accessory proteins |
| 03/05/2013 | US8388981 Babesia microti genomic clones containing novel antigens useful in the diagnosis of babesiosis |
| 03/05/2013 | US8388980 Yeast-based therapeutic for chronic hepatitis C infection |
| 03/05/2013 | US8388979 Polypeptide having affinity for envelope virus constituent and use thereof in transferring substance into cell |
| 03/05/2013 | US8388977 Diagnosis of macrophage mediated disease |
| 03/05/2013 | US8388976 Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor |
| 03/05/2013 | US8388975 Cancer antigen peptides derived from WT1 |
| 03/05/2013 | US8388974 Neovascular-targeted immunoconjugates |
| 03/05/2013 | US8388973 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 03/05/2013 | US8388972 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| 03/05/2013 | US8388971 Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses |
| 03/05/2013 | US8388970 KIR-binding agents and methods of use thereof |
| 03/05/2013 | US8388969 Interleukin-1 alpha antibodies and methods of use |
| 03/05/2013 | US8388968 Compositions and methods for increasing muscle growth |
| 03/05/2013 | US8388967 Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies |
| 03/05/2013 | US8388966 Combination treatment of pancreatic cancer |
| 03/05/2013 | US8388965 Antibodies that bind IL-4 and/or IL-13 and their uses |
| 03/05/2013 | US8388964 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| 03/05/2013 | US8388962 Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
| 03/05/2013 | US8388961 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 03/05/2013 | US8388960 Elimination of heterogeneous or mixed cell population in tumors |
| 03/05/2013 | US8388959 Anti-fXI antibodies and methods of use |
| 03/05/2013 | US8388958 Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| 03/05/2013 | US8388957 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| 03/05/2013 | US8388956 Interleukin-1 alpha antibodies and methods of use |
| 03/05/2013 | US8388955 Fc variants |
| 03/05/2013 | US8388954 Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form |
| 03/05/2013 | US8388946 Bacteriophage-containing therapeutic agents |
| 03/05/2013 | US8388944 Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions |
| 03/05/2013 | US8388933 Multimeric protein toxins to target cells having multiple identifying characteristics |
| 03/05/2013 | CA2595610C Antibodies directed to angiopoietin-2 and uses thereof |
| 03/05/2013 | CA2570050C Heart and skeletal muscle inflammation (hsmi) virus |
| 03/05/2013 | CA2552004C Methods for tailoring the immune response to an antigen or immunogen |
| 02/28/2013 | WO2013029033A2 Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures |
| 02/28/2013 | WO2013028738A1 Herpes simplex virus nanoemulsion vaccine |
| 02/28/2013 | WO2013028541A1 Vegf-binding protein for blockade of angiogenesis |
| 02/28/2013 | WO2013028442A1 Anti-tie2 antibodies uses thereof |
| 02/28/2013 | WO2013028400A1 Attenuated fish vaccine following culture in iron limited media |
| 02/28/2013 | WO2013028334A2 Use of small molecules in methods for purification of biomolecules |
| 02/28/2013 | WO2013028231A1 Anti-ox40 antibodies and methods of using the same |
| 02/28/2013 | WO2013028137A1 A protein involved in detection of cancer metastasis and a treatment thereof |
| 02/28/2013 | WO2013027802A1 Novel anti-ddr1 antibody having anti-tumor activity |
| 02/28/2013 | WO2013027658A1 Cartilage/bone destruction suppressor |
| 02/28/2013 | WO2013027356A1 Antibody and antibody-containing composition |
| 02/28/2013 | WO2013027063A1 Chemically programmable immunity |
| 02/28/2013 | WO2013026887A1 Microorganisms carrying a tumor antigen |
| 02/28/2013 | WO2013026878A1 Anti-vcam-1 nanobodies |
| 02/28/2013 | WO2013026839A1 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| 02/28/2013 | WO2013026837A1 Bispecific t cell activating antigen binding molecules |
| 02/28/2013 | WO2013026833A1 Bispecific t cell activating antigen binding molecules |
| 02/28/2013 | WO2013026831A1 Bispecific antigen binding molecules |
| 02/28/2013 | WO2013026763A1 Method for manufacturing protein solutions and their concentration |
| 02/28/2013 | WO2013026452A1 Method for removing immunosuppresive properties of hiv envelope glycoproteins |
| 02/28/2013 | WO2013026401A1 Compositions containing diverse natural antigens and uses thereof in balancing immune responses |
| 02/28/2013 | WO2013026385A1 Preparation method for quadrivalent meningococcal polysaccharide vaccine |
| 02/28/2013 | WO2013026099A1 Fn14 binding proteins and uses thereof |
| 02/28/2013 | WO2013003680A8 Anti-c-met antibody formulations |
| 02/28/2013 | WO2012178078A3 Use of yscf, truncated yscf and yscf homologs as adjuvants |
| 02/28/2013 | WO2012166991A8 S-nitrosylation of glucosylating toxins and uses therefor |
| 02/28/2013 | WO2012162637A3 Vaccine adjuvants from self-assembling peptides |
| 02/28/2013 | WO2012162342A3 Influenza vaccines containing modified adenovirus vectors |
| 02/28/2013 | WO2012151248A3 FORMULATION FOR ANTI-α4β7 ANTIBODY |
| 02/28/2013 | WO2012151247A3 FORMULATION FOR ANTI-α4β7 ANTIBODY |